GLPwatch
Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!
Expert Opin Drug Saf · 2023
Last updated 2026-05-28| Journal | Expert Opin Drug Saf, 2023 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 1.12 |
| NIH percentile | 54 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 37584280 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.